Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conestat alfa prophylaxis for idiopathic non-histaminergic acquired angioedema
NL-OMON49738Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of conestat alfa in Idiopathic non-histaminergic acquired angioedema (InH-AAE), sponsored by University Medical Center Utrecht. Primary endpoint: Mean monthly attack frequency during treatment. Started Mar 2018; status: active, not recruiting.
02
Drugs
conestat alfa
03
Conditions
Idiopathic non-histaminergic acquired angioedema (InH-AAE)
Beyond the preview
Go deeper on NL-OMON49738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49738.